- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on BRAF V600E Metastatic NSCLC
Total 231 results
-
Pierre Fabre MedicamentCompletedMelanoma | BRAF V600E Unresectable or Metastatic Melanoma | BRAF V600E Metastatic NSCLCChina
-
Novartis PharmaceuticalsRecruitingRare Unresectable or Metastatic BRAF V600E Mutation-positive Solid TumorsUnited States
-
AIO-Studien-gGmbHUniversitätsklinikum Hamburg-Eppendorf; Merck Serono GmbH, Germany; Pierre Fabre...RecruitingColorectal Cancer | Colon Cancer | BRAF V600 Mutation | BRAF V600E | Localized CancerGermany
-
Daping Hospital and the Research Institute of Surgery...Not yet recruitingNSCLC | Advanced Cancer | Stage IV NSCLC | BRAF V600E Mutation | Stage IIIB NSCLC
-
Daiichi Sankyo, Inc.PlexxikonTerminatedV600-mutated BRAF Unresectable Melanoma | V600-mutated BRAF Metastatic Melanoma | Stage III or Stage IV Metastatic Melanoma That Has Not Been Previously Treated With a Selective BRAF InhibitorUnited States, Germany, France
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI); PfizerTerminatedGlioblastoma | High Grade Glioma | Gliosarcoma | Anaplastic Astrocytoma | Anaplastic Pleomorphic Xanthoastrocytoma | BRAF V600E | BRAF V600KUnited States
-
West China HospitalRecruitingBRAF V600E-mutated /MSS Metastatic Colorectal Cancer | Vemurafenib (BRAFi) Plus Cetuximab (EGFRi) Combined With PD-1 Monoclonal AntibodyChina
-
PfizerCompletedSolid Tumors Harboring a BRAF V600 MutationUnited States, France, Italy, Singapore, Australia, Spain, Switzerland, Canada, Belgium
-
Asan Medical CenterUnknownCancer | Lung Cancer Metastatic | BRAF V600EKorea, Republic of
-
Pierre Fabre MedicamentPfizer; Merck KGaA, Darmstadt, Germany; Ono Pharmaceutical Co. LtdCompletedBRAF V600E-mutant Metastatic Colorectal CancerFrance, Italy, United States, Spain, United Kingdom, Belgium, Austria, Japan, Netherlands
-
Pierre Fabre MedicamentClinactCompletedMetastatic Colorectal Cancer | BRAF V600E Mutation PositiveFrance, United Kingdom, Spain, Belgium, Germany, Italy, Austria
-
UNICANCERPierre Fabre MedicamentRecruitingMetastatic Colorectal Cancer | BRAF V600E Mutation PositiveFrance
-
National Cancer Institute (NCI)TerminatedMetastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | BRAF V600E Mutation Present | BRAF V600K Mutation Present | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7United States
-
Dr. Ronnie ShapiraNot yet recruitingMetastatic Melanoma | Malignant Melanoma | Immunotherapy | Malignant Melanoma Stage IV | BRAF V600E
-
Pierre Fabre MedicamentMerck KGaA, Darmstadt, GermanyActive, not recruitingMetastatic Colorectal Cancer | BRAF V600EChina
-
PfizerMerck KGaA, Darmstadt, Germany; Ono Pharmaceutical Co. Ltd; Pierre Fabre MedicamentCompletedBRAF V600E-mutant Metastatic Colorectal CancerUnited States, Spain, Korea, Republic of, United Kingdom, Australia, Czechia, Taiwan, Belgium, France, Hungary, Canada, Japan, Russian Federation, Netherlands, Israel, Germany, Turkey, Austria, Brazil, Poland, Italy, Argentina, Chile, Denmar... and more
-
Anita TurkEli Lilly and CompanyTerminatedCancer | Cancer Metastatic | BRAF V600E | MEK1 Gene Mutation | MEK2 Gene Mutation | ERK Mutation | RAF1 Gene MutationUnited States
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Metastatic Malignant Solid Neoplasm | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable Solid Neoplasm | BRAF V600E Mutation Present | BRAF V600K Mutation Present | Stage IIIA Cutaneous Melanoma... and other conditionsUnited States
-
National Human Genome Research Institute (NHGRI)CompletedBRAF V600E MutationUnited States
-
University Hospital TuebingenTerminatedMetastatic Melanoma (Carrying BRAF V600 Mutation)Germany
-
Novartis PharmaceuticalsRecruitingBRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid TumorJapan
-
Pierre Fabre MedicamentBiotrialActive, not recruitingMelanoma | Metastatic Melanoma | Unresectable Melanoma | BRAF V600 MutationFrance
-
Pierre Fabre MedicamentRecruitingMetastatic Melanoma | Melanoma (Skin) | BRAF V600 MutationPortugal
-
Novartis PharmaceuticalsCompletedBRAF v600 Mutated Metastatic MelanomaUnited States
-
Sun Yat-sen UniversityNot yet recruitingNSCLC | BRAF V600 Mutation | MET Exon 14 MutationChina
-
Henan Cancer HospitalCompletedWild-type KRAS,NRAS and BRAF V600E Metastatic Colorectal Cancer
-
Genentech, Inc.CompletedMetastatic Melanoma, BRAF V600 Mutation PositiveKorea, Republic of, Russian Federation, Israel, United States
-
Pierre Fabre MedicamentBiotrialCompletedMelanoma | Metastatic Melanoma | Unresectable Melanoma | BRAF V600 MutationFrance
-
ABM Therapeutics Shanghai Company LimitedRecruitingAdvanced Solid Tumor | BRAF V600 MutationChina
-
Intergruppo Melanoma ItalianoActive, not recruiting
-
Federation Francophone de Cancerologie DigestiveMerck Sharp & Dohme LLC; Pierre Fabre LaboratoriesRecruitingColorectal Cancer | BRAF V600E Mutation PositiveFrance
-
Pierre Fabre MedicamentWithdrawnHepatic Impairment | Metastatic Melanoma | Unresectable Melanoma | BRAF V600 MutationSpain, Czechia, Italy
-
Black Diamond Therapeutics, Inc.RecruitingMelanoma | Colorectal Cancer | NSCLC | Solid Tumor | Metastatic Lung Cancer | Metastatic Lung Non-Small Cell Carcinoma | Metastatic Melanoma | Non-small Cell Lung Cancer | Histiocytosis | Melanoma (Skin) | Recurrent Melanoma | Thyroid Carcinoma | Thyroid Cancer | Brain Metastases | Recurrent Histiocytic and Dendritic... and other conditionsUnited States
-
Assistance Publique - Hôpitaux de ParisUnknownMelanoma BRAF V600E/K Mutated | CDNKN2A Loss DefinedFrance
-
Regina Elena Cancer InstituteRecruitingMelanoma (Skin) | Liquid Biopsy | Melanoma Stage IV | Melanoma Stage III | BRAF V600EItaly
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Musella FoundationTerminatedGlioma | Glioblastoma | BRAF V600E | Pleomorphic Xantho-AstrocytomaUnited States
-
Maastricht University Medical CenterKU Leuven; University College, London; Erasmus Medical Center; Catholic University... and other collaboratorsActive, not recruitingNSCLC Stage IV | Metastatic DiseaseNetherlands, Belgium, United Kingdom, Germany, France, Italy
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)RecruitingVemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive CraniopharyngiomaBRAF V600E Mutation Present | Papillary CraniopharyngiomaUnited States
-
Providence Health & ServicesRecruitingBRAF V600E Mutation Present | Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8 | Refractory Thyroid Gland Carcinoma | Metastatic Thyroid Gland Carcinoma | BRAF NP_004324.2:p.V600M | Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8 | Stage IVB Differentiated Thyroid Gland Carcinoma...United States
-
Jiangsu Aosaikang Pharmaceutical Co., Ltd.CompletedLocally Advanced or Metastatic NSCLCChina
-
Hospices Civils de LyonRecruitingMetastatic Breast Cancer | Metastatic NSCLC | Metastases to BoneFrance
-
Northwestern UniversityNational Cancer Institute (NCI)RecruitingColorectal Cancer | Colorectal Cancer Stage IV | Stage IV Colorectal Cancer Positive for BRAF V600E MutationUnited States
-
Maastricht Radiation OncologyKarolinska Institutet; KU Leuven; Maastricht University Medical Center; Catholic... and other collaboratorsWithdrawnNSCLC Stage IV | Limited Metastatic DiseaseNetherlands
-
Jiangsu Aosaikang Pharmaceutical Co., Ltd.CompletedLocally Advanced or Metastatic NSCLCChina
-
AstraZenecaCompletedLocally Advanced or Metastatic EGFR(+) NSCLC PatientsChina
-
AstraZenecaCompletedLocally Advanced or Metastatic EGFR Mutated NSCLC.Taiwan
-
H. Lee Moffitt Cancer Center and Research InstitutePfizerRecruitingMelanoma Stage IV | BRAF V600 Mutation | Melanoma Stage IIIUnited States
-
ABM Therapeutics CorporationTerminatedAdvanced Solid Tumor | BRAF V600 MutationUnited States
-
Pierre Fabre MedicamentIqvia Pty LtdRecruitingBRAF V600 Mutation | Metastatic Non-small Cell Lung CancerFrance
-
Novartis PharmaceuticalsActive, not recruitingBRAF V600 Colorectal CancerBelgium, Germany, Netherlands, Spain, Singapore, Australia, United Kingdom, Israel, Canada, United States